

# SparkLife A Resuscitation Company

c/o Mark Stewart  
SUNY Downstate Medical Center  
450 Clarkson Avenue  
Brooklyn, NY 11203

Mark Stewart, MD, PhD

T 973-975-2399,

mark.stewart@downstate.edu

## Novel Cardiac Defibrillation

A superior device for defibrillation based on vagus nerve stimulation.

100% effective in rats. Large animal validation in progress.

Eliminates ALL significant physician and patient concerns, including misfire and recall issues.

Primary and alternate approaches for market introduction.

A strong, multidisciplinary team.

### WHAT WE NEED:

Advice and investment to get through clinical trials and fully capture market

### Industry:

- Pharma
- Biotech
- Medical Device
- Diagnostic
- Other (declare)

### Management:

- Executive Leadership  
Mark Stewart, MD, PhD  
Rena Orman, PhD  
Jason Lazar, MD
- Board
- Scientific Advisory Board

### Number of Employees:

### Finance:

- Auditor
- Current Investors / Financing to Date  
About \$500,000 from various sources (grants and some philanthropy)
  - Amount of Financing Sought \$250,000 for remainder of large animal workStill estimating costs for first in man trials

### Legal:

- Corporate  
Pryor-Cashman (incorporation)
- IP  
University-owned IP  
Option to SparkLife

### Executive Summary:

SparkLife is a very early stage startup with technology developed by investigators at SUNY Downstate Medical Center. Our first technology is a vagus nerve stimulation-based cardioverter/defibrillator that eliminates all major problems with existing ICD or CRT-D implants.

### Company History:

The method was discovered about 5 years ago, but SparkLife is newly incorporated to move this and other technologies to market.

### Market Opportunity / Unmet Need:

About \$2.5 billion was spent globally on implantable defibrillator options with nearly \$4 billion projected in sales by 2020. Our technology is expected to be superior to all existing options because our technology addresses significant problems with existing options.

### Products/Services – Launched & Pipeline:

Implantable vagus nerve stimulation-based defibrillator. Proof of concept in small animals; nearly finished with proof of concept in large animals; plans for implantable prototype and FDA review.

### Commercial / Technical Milestones:

Proof of concept in large animals is expected within 2017; first discussions with FDA in late 2017; implantable prototype built and tested in 2018-2019; plans for first in man trials as early as 2020.

### Intellectual Property:

Patent pending.

### Competition:

ICD and CRT-D manufacturers are the only significant options. Our device eliminates problems with all such devices. VNS manufacturers do not compete because devices are used for non-cardiac conditions.

### Financial Projections (Unaudited):

Proof of concept work in large animals is funded. Planned SBIR to fund prototype development and testing. Additional SBIR funds and investment needed for first clinical testing and (depending on FDA) larger clinical trials.

### Please indicate primary purpose of Presentation:

Investment  
Business Development XX  
Other: (Please specify)